ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 233,45
0,35%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Kyverna Therapeutics Inc (KYTX)

  7. Kyverna Therapeutics Inc (KYTX) Actualités

KYTX

Kyverna Therapeutics (KYTX)

Kyverna Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KYTX
DateHeureSourceTitreSymboleSociété
14/06/202412h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYTXKyverna Therapeutics Inc
11/06/202400h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYTXKyverna Therapeutics Inc
10/06/202422h05PR Newswire (US)Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews ImmunologyNASDAQ:KYTXKyverna Therapeutics Inc
07/06/202422h06PR Newswire (US)Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024NASDAQ:KYTXKyverna Therapeutics Inc
14/05/202422h29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KYTXKyverna Therapeutics Inc
14/05/202422h05PR Newswire (US)Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:KYTXKyverna Therapeutics Inc
11/04/202423h01PR Newswire (US)Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune DiseasesNASDAQ:KYTXKyverna Therapeutics Inc
29/03/202419h59PR Newswire (US)First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in MedNASDAQ:KYTXKyverna Therapeutics Inc
26/03/202421h05PR Newswire (US)Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial ResultsNASDAQ:KYTXKyverna Therapeutics Inc
08/03/202401h26PR Newswire (US)Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple SclerosisNASDAQ:KYTXKyverna Therapeutics Inc
12/02/202422h39PR Newswire (US)Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:KYTXKyverna Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KYTX

Dernières Valeurs Consultées

NASDAQ
PRPO
Precipio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés